## TN-1197

# APPLICATIONS

## Related Substances Assay of the Drug Product Dienogest on a Kinetex<sup>®</sup> 3.5 µm XB-C18 Column According to Ph. Eur. Monograph 2732

Matthew Trass<sup>1</sup>, Simon Lomas<sup>1</sup> and Heiko Behr<sup>2</sup> <sup>1</sup>Phenomenex, Inc., 411 Madrid Ave., Torrance, CA 90501 USA <sup>2</sup>Phenomenex, Ltd., Zeppelinstr. 5, 63741 Aschaffenburg, Germany

In this technical note, we report the separation between Dienogest and Impurity F {(17-hydroxy-3,3-dimethoxyestra-5(10),9(11)-dien-17 $\alpha$ -yl)acetonitrile} using a Kinetex 3.5 µm XB-C18 HPLC column according to the Ph. Eur. Monograph 2732 related substances assay.

#### Introduction

The European Pharmacopoeia (Pharmacopoea Europaea, Ph. Eur.) is a single reference work for the quality control of medicines in the signatory states of the Convention on its elaboration. The official standards published within provide a legal and scientific basis for quality control during the development, production, and marketing processes. They concern the qualitative and quantitative composition and the tests to be carried out on medicines, on the raw materials used in production of medicines and/or substances for pharmaceutical use must therefore apply these quality standards in order to market their products. Dienogest is primarily an oral contraceptive used in combination with ethinylestradiol. However, the compound is also given in isolation for the treatment of endometriosis under the trade name Visanne.

#### Figure 1. Dienogest



..breaking with tradition<sup>™</sup>

phenomenex

#### Dr. Heiko Behr

#### European Pharmaceutical Senior Business Development Manager

In addition to chromatography, Dr. Behr has an absolute love for heavy metal music and skiing in the Alps.



#### **Materials and Methods**

The analysis was performed using an Agilent<sup>®</sup> 1100 equipped with a multiple wavelength UV detector. The Kinetex 3.5 µm XB-C18 column used for analysis was obtained from Phenomenex (Torrance, CA, USA). All solvents were purchased from Honeywell (Morristown, NJ, USA) and Sigma-Aldrich (St. Louis, MO, USA). Ph. Eur. Standard Dienogest for system suitability CRS (containing impurity F) Y0001782 was purchased from European Directorate for the Quality of Medicines & HealthCare (EDQM) – Council of Europe; Postal address: 7 Allée Kastner CS 30026 F - 67081 STRAS-BOURG (France).

### Ph. Eur. Monograph 2732

Ph. Eur. Monograph 2732 system suitability reference solution A. Dissolve 2.5 mg of Dienogest for system suitability CRS (containing impurity F) in 2 mL of acetonitrile and dilute to 5.0 mL with water.

Column:

- size: I = 0.25 m, Ø = 4.6 mm
- stationary phase: end-capped extra-dense bonded octadecylsilyl silica gel for chromatography (3.5 μm)
- temperature: 35 °C

Mobile Phase:

- A: Acetonitrile/Water for chromatography (10:90 V/V)
- B: Water for chromatography/acetonitrile (10:90 V/V)

*Gradient:* 10 % mobile phase B for 3 min to 90 % mobile phase B in 50 min

Flow Rate: 1.0 mL/min

Detection: spectrophotometer at 210 nm

Injection: 15 µL

Relative retention with reference to Dienogest (retention time = about 19 min): impurity F = about 1.1

System suitability: reference solution (A):

 resolution: minimum 4.0 between the peaks due to Dienogest and impurity Australia

Austria t: +43 (0)1-319-1301

Belaium

Canada t: +1 (800) 543-3681

China

Denmark t: +45 4824 8048

Finland

France t: +33 (0)1 30 09 21 10

f: +45 4810 6265

f: +45 4810 6265

t: +358 (0)9 4789 0063

f: +33 (0)1 30 09 21 11

**Germany** t: +49 (0)6021-58830-0

f: +49 (0)6021-58830-11

t: +91 (0)40-3012 2400

f: +91 (0)40-3012 2411

t: +353 (0)1 247 5405 f: +44 1625-501796

t: +61 (0)2-9428-6444

f: +61 (0)2-9428-6445

f: +43 (0)1-319-1300

f: +31 (0)30-2383749

f: +1 (310) 328-7768

t: +86 (0)20 2282-6668

f: +86 (0)20 2809-8130

chinainfo@phenomenex.com

nordicinfo@phenomenex.com

nordicinfo@phenomenex.com

franceinfo@phenomenex.com

anfrage@phenomenex.com

indiainfo@phenomenex.com

info@phenomenex.com

auinfo@phenomenex.com

anfrage@phenomenex.com

t: +32 (0)2 503 4015 (French) t: +32 (0)2 511 8666 (Dutch)

beinfo@phenomenex.com

# ICATIONS



### **Result and Discussion**

In this technote we report the separation between Dienogest (the Active pharmaceutical ingredient) and related impurity F ((17-hydroxy-3.3-dimethoxyestra-5(10).9(11)-dien-17 $\alpha$ -vl)acetonitrile) per the related substances section of Ph. Eur. Monograph 2732, as shown in Figure 2. The resolution between Dienogest and the related substance F is 6.22 which passes the system suitability minimum resolution requirement of 4.0.

#### Figure 2.

Dienogest reference solution (A) on a Kinetex® 3.5 µm XB-C18, 150 x 4.6 mm, R = 6.22



### Conclusion

The results shown above demonstrate that Kinetex 3.5 µm XB-C18, 150 x 4.6 mm column can be successfully used to analyze Dienogest according to Ph. Eur. Monograph 2732. Resolution between the API and impurity F for system suitability was 6.22 which is well above the minimum of 4.0 required by the Ph. Eur. monograph method.

Kinetex 3.5 µm Analytical Columns		SecurityGuard™ ULTRA Cartridges*
Phases	150 x 4.6 mm	3pk
XB-C18	00F-4744-E0	AJ0-8768
		for 4.6 mm ID

\* SecurityGuard ULTRA Cartridges require holder, Part No.: AJ0-9000

guarantee
-----------

If Phenomenex products in this technical note do not provide at least an equivalent separation as compared to other products of the same phase and dimensions, return the product with comparative data within 45 days for a FULL REFUND.

#### Terms and Conditions

Subject to Phenomenex Standard Terms and Conditions, which may be viewed at http:// www.phenomenex.com/TermsAndConditions.

#### Trademarks

Kinetex is a registered trademark and SecurityGuard is a trademark of Phenomenex. Agilent is a registered trademark of Agilent Technologies, Inc. Disclaimer

Phenomenex is not affiliated with Agilent. Comparative separations may not be representative of all applications.

© 2016 Phenomenex, Inc. All rights reserved.

Mexico t: 001-800-844-5226 f: 001-310-328-7768

#### The Netherlands t: +31 (0)30-2418700 f: +31 (0)30-2383749

Luxembourg

t: +31 (0)30-2418700

f: +31 (0)30-2383749

nlinfo@phenomenex.com

tecnicomx@phenomenex.com

nlinfo@phenomenex.com

## New Zealand t: +64 (0)9-4780951

f: +64 (0)9-4780952 nzinfo@phenomenex.com

## Norway t: +47 810 02 005

f: +45 4810 6265 nordicinfo@phenomenex.com

- Puerto Rico t: +1 (800) 541-HPLC f +1 (310) 328-7768
- info@phenomenex.com

#### Spain

t: +34 91-413-8613 f: +34 91-413-2290 espinfo@phenomenex.com

## **Sweden** t: +46 (0)8 611 6950

- f: +45 4810 6265 nordicinfo@phenomenex.com

#### United Kingdom

- t: +44 (0)1625-501367 f: +44 (0)1625-501796
- ukinfo@phenomenex.com

#### USA

t: +1 (310) 212-0555 f: +1 (310) 328-7768 info@phenomenex.com

# All other countries Corporate Office USA t: +1 (310) 212-0555

- f: +1 (310) 328-7768
- info@phenomenex.com

## Italv

India

Ireland

- t: +39 051 6327511
- f: +39 051 6327555
- italiainfo@phenomenex.com

eireinfo@phenomenex.com

#### www.phenomenex.com

Phenomenex products are available worldwide. For the distributor in your country, contact Phenomenex USA, International Department at international@phenomenex.com